Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

Biogen Idec Ma Inc.

Padlock Therapeutics, Inc.

Millennium Pharmaceuticals Limited

Biogen, Incorporated

Other

Millenium Pharmaceuticals, Inc.

Boigen Ma Inc.

Arrakis Therapeutics, Inc.

Gnanasambandam Kumaravel

Kevin Guckian

Bin Ma

Jermaine Thomas

Edward Yin-Shiang Lin

Arthur G Taveras

Guo Zhu Zheng

Richard Dana Caldwell

Zhili Xin

Lihong Sun

Hairuo Peng

Daniel M Scott

Lei Zhang

Timothy Raymond Chan

Xiaogao Liu

Deping Wang

Sha Mi

Brian T Hopkins

Bing Guan

Noel Aaron Powell

Alexey Alexandrovich Lugovskoy

Wen-Cherng Lee

Tracy J Jenkins

Joseph P Lyssikatos

Daniel A Erlanson

Russell Colyn Petter

Rajesh Devraj

Zhan Shi

Heather Tye

Cristina Lecci

Jeffrey Vessels

Min Zhong

Junfa Fan

Patrick R Conlon

Minna Bui

Zhaohui Shao

Hua Miao

Mirco Meniconi

Art Taveras

Doug Marcotte

Hiroko Tanaka

Kevin Koch

John Howard Jones

Brian Raimundo

Julio Hernan Cuervo

Laura Silvian

Laura Gleave

Jennifer Cossrow

James E Dowling

Jordan Palfrey

Thomas Wynn

Edward Beaumont

Philip Stephen Kerry

Brian Stuart Lucas

Pui Leng Loke

Carl Leslie North

Carol L Ensinger

Elise Gadouleau

Nat Monck

Robert Meissner

Irina Leaf

Jeremy Duffield

Alexey V Ishchenko

William F Kiesman

Weirong Chen

Holly Atton

Mark Peter Ridgill

Joseph Arndt

Kurt D Van Vloten

Adrian Kotey

Benjamin Lane

Gang Yao

Jeffery Vessels

Thomas Krulle

Lloyd Franklin

Adam Littke

Kostas Papadopoulos

Philip A Woods

He Xi Chang

Ko Chung Lin

Chi B Vu

Michael Frederick Parker

Jianhua Chao

Kevin Lewis Otipoby

Donovan Noel Chin

Nathan Genung

Shelley Anne Parrott

Jennifer C Petter

Neil Kubica

Lee Bowles

Steve Bromidge

Sophie Cooper

Ian Wigginton

Ma Bin

Hexi Chang

Herschel Mukherjee

Chao Fang

Jonathan Craig Blain

Daniel Erlanson

Andrea Bertolotti-Ciarlet

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Heteroaryl inhibitors of PAD4

The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcripts that bind compounds and are thus druggable, methods of screening drug candidates, and methods of determining drug binding sites and/or accessible or reactive sites on a target RNA.

Nucleic acid-binding photoprobes and uses thereof

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Biaryl inhibitors of Bruton's tyrosine kinase

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease. 

IRAK4 inhibiting agents

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

S1P modulating agents

Biaryl inhibitors of Bruton'S tyrosine kinase

The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders. 

Covalent inhibitors of PAD4

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Bruton's tyrosine kinase inhibitors

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

SIP modulating agents

Biaryl bruton's tyrosine kinase inhibitors

Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

Compounds that are S1P modulating agents and/or ATX modulating agents

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Growing community of inventors

Lexington, MA, United States of America

Gnanasambandam Kumaravel